Iron saccharate 蔗糖铁
CAS 8047-67-4 MFCD00166305
化学结构图
SMILES: O=C([O-])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)[O-].O=C([O-])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)[O-].O=C([O-])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)[O-].[Fe+3].[Fe+3]
化学属性
| Mol. Formula | [Na2Fe5O8(OH) • 3H2O]n •(C12H22O11)m |
|---|---|
| Mol. Weight | |
| Melting Point | 168-171 |
别名和识别编码
| CAS Number | 8047-67-4 |
|---|---|
| Chemical Name | Iron saccharate |
| Synonym | ######## Colliron IV, Feoject Colliron IV, Feojectin, Ferric Hydroxide Sucros Complex, Ferrivenin FERRIC OXIDE, SACCHARATED Feojectin Ferric oxide, saccharated Ferric saccharate Ferric saccharate ...iron oxide (mix.) Ferrivenin IRONSUCROSEUSP Iron Saccharate {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} |
| EC Number | 232-464-7 |
| MDL Number | MFCD00166305 |
| Chemical Name Translation | 蔗糖铁 |
| PubChem Substance ID | 11377634 |
| InChI | InChI=1S/3C6H10O8.2Fe/c3*7-1(3(9)5(11)12)2(8)4(10)6(13)14;;/h3*1-4,7-10H,(H,11,12)(H,13,14);;/q;;;2*+3/p-6/t3*1-,2-,3-,4+;;/m000../s1 |
| Canonical SMILES | N/A |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Carbohydrates & Derivatives
- Pharmaceuticals
- Intermediates & Fine Chemicals
产品应用
- Iron Saccharate has been used to treat iron deficiency and iron deficiency anemia associated with different chronic diseases.
相关文献及参考
- [2]. Kristin E Brandt, et al. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87.
- [3]. Ko-Lin Kuo, et al. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606.
- [4]. Richard A Zager, et al. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76.
- Stein, J., et al.: Curr. Med. Res. Opinion,?28,?241 (2012),
- [1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262.
- [1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262.
- [2]. Kristin E Brand
安全信息
GHS Symbol
- S24/25 Avoid contact with skin and eyes 避免皮肤和眼睛接触；
- P262 Do not get in eyes, on skin, or on clothing. 不要接触眼睛，皮肤或衣服。
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1560 mg/kg/13W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - other reproductive system tumors REFERENCE : BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 60,708,1989
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 104 gm/kg/13W-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application REFERENCE : JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. Volume(issue)/page/year: 24,109,1960
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 148 gm/kg/74W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Tumorigenic - tumors at site of application REFERENCE : BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,947,1959
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 150 gm/kg/I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Tumorigenic - tumors at site of application REFERENCE : BECCAN Annual Report--Cancer Research Campaign. (Cancer Research Campaign,
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 180 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,193,1982
TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 150 mg(Fe)/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 10,375,1955
其他信息
- MOL 文件:8047-67-4.mol
